| Abstrakt: |
Objective: To evaluate the therapeutic effect of Glycyrrhetinic Acid on cough variant asthma (CVA) mice and to investigate the possible mechanism in reducing lung inflammation. Methods: 48 young female Balb/c mice were divided into Control, CVA, Prednisone Acetate, Glycyrrhetinic Acid high-dose, Glycyrrhetinic Acid middle-dose and Glycyrrhetinic Acid lowdose groups randomly, with 8 mice in each group. The CVA mice model was established by ovalbumin (OVA) sensitization and OVA challenge, the animal asthma behavior was observed after drug administration, and the index of the lung of mice were recorded. The level of OVAsIgE in the bronchoalveolar lavage fluid (BALF) was tested by ELISA. The pathological changes of the lung tissue were observed by Hematoxylin and Eosin (H&E) staining. The protein expressions of T-bet, IFN-γ, Gata3, IL-4 and IL-13 in the lung tissue were determined by Western blot. Results: Compared with the CVA group, the index of lung of mice, the OVA-sIgE level in BALF and expression levels of Th2-related factor in the lung tissue of mice in Prednisone Acetate and Glycyrrhetinic Acid groups were significantly decreased (P< 0.05 or P< 0.01), the infiltration of inflammatory cells in the lung tissue was reduced, while expressions of Th1-related factor in the lung tissue was significantly increased (P< 0.05 or P< 0.01). Conclusion: Glycyrrhetinic acid has therapeutic effect on CVA mice, the underlying mechanism of Glycyrrhetinic acid alleviating lung impairment and airway inflammation may be associated with mediating the Th1/Th2 imbalance in the lung tissue. [ABSTRACT FROM AUTHOR] |
